Preliminary report of a drug trial conducted at Leprosy Relief Rural Centre, Chettipatty, South India.

The drug combination (rifampicin + Isoprodian) therapy continues for 7 cases, it has been stopped for 1 9 cases-out of which 1 0 cases receive dapsone treatment ranging from 2 5 to 400 mgf week , the other 9 cases are without DDS subj ected to further observation and follow-u p . Ali, b u t 2 cases could again resume work which for s o m e of t h e m h a d n o t been possible for years gone by. The experience gained till now with the drug combination therapy rifampicin + Isoprodian allows us to state that it no doubt means a noteworthy progresso This is especially so in those L and BL cases who never could tolerate and constant1y reacted adversely to ali the anti-Ieprosy drugs that are commonly in use. These patients hitherto constitute an insurmountable m edicai and social problem.